157 related articles for article (PubMed ID: 19711497)
1. Analysis of Maryland cancer patient participation in National Cancer Institute-supported cancer treatment clinical trials.
Baquet CR; Ellison GL; Mishra SI
J Health Care Poor Underserved; 2009 May; 20(2 Suppl):120-34. PubMed ID: 19711497
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials.
Baquet CR; Ellison GL; Mishra SI
J Clin Oncol; 2008 Jul; 26(20):3380-6. PubMed ID: 18612153
[TBL] [Abstract][Full Text] [Related]
3. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.
Sateren WB; Trimble EL; Abrams J; Brawley O; Breen N; Ford L; McCabe M; Kaplan R; Smith M; Ungerleider R; Christian MC
J Clin Oncol; 2002 Apr; 20(8):2109-17. PubMed ID: 11956272
[TBL] [Abstract][Full Text] [Related]
4. The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies.
Mishkin G; Minasian LM; Kohn EC; Noone AM; Temkin SM
Gynecol Oncol; 2016 Dec; 143(3):611-616. PubMed ID: 27697287
[TBL] [Abstract][Full Text] [Related]
5. Insights From Building a New National Cancer Institute Community Oncology Research Program Site.
Saphner T; Thompson MA; Planton S; Singh M; Glandt N; Robinson L; DeBartolo J
WMJ; 2016 Aug; 115(4):191-5. PubMed ID: 29099156
[TBL] [Abstract][Full Text] [Related]
6. Power of an effective clinical conversation: improving accrual onto clinical trials.
Parreco LK; DeJoice RW; Massett HA; Padberg RM; Thakkar SS
J Oncol Pract; 2012 Sep; 8(5):282-6. PubMed ID: 23277764
[TBL] [Abstract][Full Text] [Related]
7. Patterns of National Cancer Institute-Sponsored Clinical Trial Enrollment in Black Adolescents and Young Adults.
Roth M; Beauchemin M; Kahn JM; Bleyer A
Cancer Med; 2021 Nov; 10(21):7620-7628. PubMed ID: 34592782
[TBL] [Abstract][Full Text] [Related]
8. Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: a current view and opportunities for improvement.
Hawk ET; Habermann EB; Ford JG; Wenzel JA; Brahmer JR; Chen MS; Jones LA; Hurd TC; Rogers LM; Nguyen LH; Ahluwalia JS; Fouad M; Vickers SM
Cancer; 2014 Apr; 120 Suppl 7(0 7):1113-21. PubMed ID: 24643649
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with biomedical research participation within community-based samples across 3 National Cancer Institute-designated cancer centers.
Barrett NJ; Rodriguez EM; Iachan R; Hyslop T; Ingraham KL; Le GM; Martin K; Haring RC; Rivadeneira NA; Erwin DO; Fish LJ; Middleton D; Hiatt RA; Patierno SR; Sarkar U; Gage-Bouchard EA
Cancer; 2020 Mar; 126(5):1077-1089. PubMed ID: 31909824
[TBL] [Abstract][Full Text] [Related]
10. Enrollment and Racial Disparities in Cancer Treatment Clinical Trials in North Carolina.
Zullig LL; Fortune-Britt AG; Rao S; Tyree SD; Godley PA; Carpenter WR
N C Med J; 2016; 77(1):52-8. PubMed ID: 26763244
[TBL] [Abstract][Full Text] [Related]
11. Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program.
Kaluzny A; Brawley O; Garson-Angert D; Shaw J; Godley P; Warnecke R; Ford L
J Natl Cancer Inst; 1993 Dec; 85(23):1945-50. PubMed ID: 8230286
[TBL] [Abstract][Full Text] [Related]
12. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.
Korn EL; Freidlin B; Mooney M; Abrams JS
J Clin Oncol; 2010 Dec; 28(35):5197-201. PubMed ID: 21060029
[TBL] [Abstract][Full Text] [Related]
13. A surveillance system for monitoring, public reporting, and improving minority access to cancer clinical trials.
Carpenter WR; Tyree S; Wu Y; Meyer AM; DiMartino L; Zullig L; Godley PA
Clin Trials; 2012 Aug; 9(4):426-35. PubMed ID: 22761398
[TBL] [Abstract][Full Text] [Related]
14. Leveraging National Cancer Institute Programmatic Collaboration for Uterine Cervix Cancer Patient Accrual in Puerto Rico.
Kunos CA; Massett HA; Galassi A; Walker JL; Good MJ; Díaz LB; McCaskill-Stevens W
Front Oncol; 2018; 8():102. PubMed ID: 29692980
[TBL] [Abstract][Full Text] [Related]
15. The impact of socioeconomic status and race on trial participation for older women with breast cancer.
Gross CP; Filardo G; Mayne ST; Krumholz HM
Cancer; 2005 Feb; 103(3):483-91. PubMed ID: 15597407
[TBL] [Abstract][Full Text] [Related]
16. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
Cheng SK; Dietrich MS; Dilts DM
Clin Cancer Res; 2010 Nov; 16(22):5557-63. PubMed ID: 21062929
[TBL] [Abstract][Full Text] [Related]
17. Maryland's Special Populations Cancer Network: cancer health disparities reduction model.
Baquet CR; Mack KM; Bramble J; DeShields M; Datcher D; Savoy M; Hummel K; Mishra SI; Brooks SE; Boykin-Brown S
J Health Care Poor Underserved; 2005 May; 16(2):192-206. PubMed ID: 15937382
[TBL] [Abstract][Full Text] [Related]
18. Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.
Bennette CS; Ramsey SD; McDermott CL; Carlson JJ; Basu A; Veenstra DL
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26714555
[TBL] [Abstract][Full Text] [Related]
19. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities.
Stewart JH; Bertoni AG; Staten JL; Levine EA; Gross CP
Ann Surg Oncol; 2007 Dec; 14(12):3328-34. PubMed ID: 17682824
[TBL] [Abstract][Full Text] [Related]
20. Participation in cancer clinical trials: race-, sex-, and age-based disparities.
Murthy VH; Krumholz HM; Gross CP
JAMA; 2004 Jun; 291(22):2720-6. PubMed ID: 15187053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
